TSUBOTA LABORATORY INCORPORATED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 377 JPY | -1.82% |
|
+4.72% | +12.54% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 640M 4.11M | Sales 2023 | 954M 6.12M | Capitalization | 20.98B 135M |
|---|---|---|---|---|---|
| Net income 2022 | 153M 982K | Net income 2023 | 90M 578K | EV / Sales 2022 * | - |
| Net cash position 2022 | 951M 6.1M | Net cash position 2023 | 2.02B 12.99M | EV / Sales 2023 | 19.9 x |
| P/E ratio 2022 * |
-
| P/E ratio 2023 |
236
x | Employees | 10 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 26.25% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.82% | ||
| 1 week | +4.72% | ||
| Current month | +5.90% | ||
| 1 month | +6.20% | ||
| 3 months | +30.45% | ||
| 6 months | -6.91% | ||
| Current year | +12.54% |
1 week
351.00
391.00
1 month
339.00391.00
Current year
252.00511.00
1 year
252.00738.00
3 years
252.001 447.00
5 years
252.001 447.00
10 years
252.001 447.00
| Managers | Title | Age | Since |
|---|---|---|---|
Kazuo Tsubota
FOU | Founder | 69 | 12-05-27 |
Takanari Shimizu
ADM | Chief Administrative Officer | - | - |
Shinichiro Kondo
CTO | Chief Tech/Sci/R&D Officer | 55 | 15-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Shinichi Koizumi
BRD | Director/Board Member | 68 | 20-05-31 |
Kazuo Tsubota
FOU | Founder | 69 | 12-05-27 |
Shintaro Yamada
BRD | Director/Board Member | 51 | 12-04-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 377 | -1.82% | 65 400 |
| 24-05-16 | 384 | +2.40% | 37,000 |
| 24-05-15 | 375 | -0.79% | 61,800 |
| 24-05-14 | 378 | +5.88% | 150,100 |
| 24-05-13 | 357 | -0.83% | 36,100 |
Delayed Quote Japan Exchange, May 17, 2024 at 02:00 am EDT
More quotes
Tsubota Laboratory Inc is a Japan-based company mainly engaged in the research and development of new treatments for myopia, dry eye, and presbyopia. The Company operates with a B2B business model. The model generates revenue from lump-sum payments under joint research and development agreements and licensing agreements with partner companies, milestone payments, and royalties under post-commercialization (post-launch) loyalty agreements and creates new value by investing the profits in the new research. The Company is also engaged in the research and development of products for adults that treat depression and dementia, improve sleep and increase concentration.
Calendar
2024-08-08
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +12.54% | 63.26M | |
| +30.99% | 50.85B | |
| +1.46% | 42.82B | |
| +48.77% | 42.03B | |
| -4.22% | 29.55B | |
| +11.03% | 26.11B | |
| -22.28% | 19.13B | |
| +7.54% | 13.05B | |
| +26.80% | 12.16B | |
| +23.30% | 12.08B |
- Stock Market
- Equities
- 4890 Stock
